Fiber optic connectors are a substantial fragment of the global telecommunication industry. Optical fibers are joined using fiber optic connectors, which allow the light conduction between two consecutive optical fibers. An additional im…
DelveInsight's "Oral Mucositis - Epidemiology Forecast To 2025" report provides an overview of the disease and global historical and forecasted epidemiological data of Oral Mucositis for the seven major markets i.e. United States, EU5 (France, Germany, Italy, Spain, UK) and Japan till 2025.
Oral Mucositis is considered as one of the most common oral problems associated with cancer therapy. It is reported that Oral mucositis occurs in up to 20% to 40% of adult cancer patients receiving conventional chemotherapy for solid tumors, about 80% of patients receiving high-dose chemotherapy before haematopoietic stem cell transplantation, and almost all patients receiving radiotherapy for head and neck cancer. The Oral mucositis also occurs in the 70% of the patients with cancers of the mouth, oropharynx, hypopharynx, larynx, nasopharynx, and salivary glands. It has been reported that approximately 500,000 cases of oral mucositis occurs in U.S. The incidence of oral mucositis varies across populations of patients with cancer and is related to individual patient factors and the type of therapy being received.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house forecast model analysis by the team of industry experts.
- The report covers the disease overview including pathophysiology, symptoms, diagnosis, disease management, and current treatment options
- The report also covers the detailed global historical and forecasted epidemiological data covering United States, EU5 and Japan from 2015-2025
- The report includes the overall incidence, grade specific, gender specific and indication specific incidence of Oral Mucositis in the 7MM- United States, EU5 (France, Germany, Italy, Spain and UK) and Japan